Alzamend Neuro, Inc. (ALZN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q1 FY2027, filed Sep 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ALZN SEC filings page.
This page shows Alzamend Neuro, Inc. (ALZN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Alzamend remains a development-stage business whose losses are consuming cash while financing increasingly supports operations.
Earnings quality is weak in a specific way: FY2026's net loss of$8.8M was close to its operating cash outflow of$8.1M , so reported losses are translating into near-term funding needs rather than being mainly non-cash accounting charges. With only$4.8M of financing inflow against that outflow, assets fell to$2.1M and equity to$733K .
Research spending accelerated from
The balance-sheet cushion narrowed materially: total liabilities increased from
Financial Health Signals
Alzamend Neuro, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Alzamend Neuro, Inc. passes 1 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Alzamend Neuro, Inc. reported a net loss of $8.8M while operations used $8.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Alzamend Neuro, Inc. reported an operating loss of $8.8M against $7K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Alzamend Neuro, Inc.'s EBITDA was -$3.0M in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 12.2% from the same quarter a year earlier.
Alzamend Neuro, Inc. reported -$3.0M in net income in Q1 2027. This represents a decrease of 12.0% from the same quarter a year earlier.
Alzamend Neuro, Inc. earned -$0.68 per diluted share (EPS) in Q1 2027. Against the prior quarter it is up 8.1%.
Not reported for Q1 2027.
Cash & Balance Sheet
Alzamend Neuro, Inc. held $7.6M in cash as of Q1 2027; long-term debt is not reported for that period.
Not reported for Q1 2027.
Not reported for Q1 2027.
Margins & Returns
Alzamend Neuro, Inc.'s ROE was -52.2% in Q1 2027, measuring profit generated per dollar of shareholder equity. This is down 1.6 percentage points from the same quarter a year earlier.
Not reported for Q1 2027.
Not reported for Q1 2027.
Not reported for Q1 2027.
Capital Allocation
Alzamend Neuro, Inc. invested $1.1M in research and development in Q1 2027. This represents a decrease of 37.6% from the same quarter a year earlier.
Not reported for Q1 2027.
Not reported for Q1 2027.
ALZN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $1.1M-37.6% | N/A | $1.3M+186.0% | $176K-43.3% | $1.7M+742.7% | N/A | $447K-76.6% | $311K-84.4% |
| SG&A Expenses | $1.9M+102.2% | N/A | $919K+55.7% | $822K-21.5% | $959K+26.9% | N/A | $590K-21.4% | $1.0M+15.7% |
| Operating Income | -$3.0M-12.0% | N/A | -$2.2M-111.8% | -$998K+26.5% | -$2.7M-180.6% | N/A | -$1.0M+61.0% | -$1.4M+53.2% |
| EBITDA | -$3.0M-12.2% | N/A | -$2.2M-111.8% | -$970K+27.9% | -$2.7M-181.4% | N/A | -$1.0M+61.3% | -$1.3M+53.4% |
| Interest Expense | $2K-19.3% | N/A | $1K-33.8% | $3K-24.2% | $2K-79.3% | N/A | $2K-18.9% | $3K-18.9% |
| Net Income | -$3.0M-12.0% | N/A | -$2.2M-111.6% | -$1.0M+26.5% | -$2.7M-177.4% | N/A | -$1.0M+61.0% | -$1.4M+53.1% |
| EPS (Basic) | -$0.68+46.9% | -$0.74+58.4% | -$0.58+66.9% | -$0.30+91.7% | -$1.28+88.8% | -$1.78+86.7% | -$1.75+53.6% | -$3.61+18.5% |
| EPS (Diluted) | -$0.68 | -$0.74+58.4% | -$0.58 | -$0.30 | -$1.28 | -$1.78 | -$1.75+53.6% | -$3.61 |
| Diluted Shares (Avg) | 4M | N/A | 4M | 3M | 2M | N/A | 611,978-13.2% | 392,411 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
ALZN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.5M+35.0% | $2.1M-54.8% | $4.0M-3.2% | $5.1M+1.7% | $6.3M+278.9% | $4.6M+628.8% | $4.2M+433.5% | $5.0M+409.1% |
| Current Assets | $8.3M+39.2% | $1.8M-57.8% | $3.7M-6.3% | $4.7M-1.0% | $5.9M+318.6% | $4.2M+817.6% | $3.9M+565.0% | $4.8M+509.7% |
| Cash & Equivalents | $7.6M+35.1% | $711K-82.0% | $2.7M-19.2% | $4.4M+8.7% | $5.6M+370.8% | $3.9M+950.0% | $3.4M+1087.2% | $4.1M+1945.7% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $2.7M+178.6% | $1.3M+112.1% | $1.9M+155.9% | $717K-42.8% | $983K-65.9% | $635K-80.3% | $726K-85.6% | $1.3M-65.8% |
| Total Equity | $5.8M+8.6% | $733K-81.5% | $2.2M-36.2% | $4.4M+16.6% | $5.3M+540.8% | $4.0M+253.0% | $3.4M+180.9% | $3.8M+239.9% |
| Retained Earnings | -$70.3M-14.9% | -$67.3M-15.0% | -$64.4M-12.3% | -$62.2M-10.3% | -$61.2M-11.4% | -$58.5M-8.4% | -$57.4M-8.0% | -$56.4M-11.7% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Current Liabilities, Non-Current Liabilities, Long-Term Debt.
ALZN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.1M+51.8% | -$2.8M-306.2% | -$1.7M-22.0% | -$1.2M+65.5% | -$2.4M-123.8% | -$689K+51.7% | -$1.4M+29.9% | -$3.4M-124.7% |
| Depreciation & Amortization | $28K0.0% | $28K+118.2% | $28K+118.2% | $28K+118.2% | $28K+118.2% | $13K0.0% | $13K0.0% | $13K0.0% |
| Stock-Based Compensation | $77K+79.9% | N/A | N/A | N/A | $43K-47.2% | N/A | $81K-56.5% | $81K-53.7% |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | -$210K | $0 | $0 |
| Financing Cash Flow | $8.0M+98.7% | $795K-46.6% | $0-100.0% | $0-100.0% | $4.0M+105.5% | $1.5M-2.0% | $689K-67.4% | $6.3M |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
ALZN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -52.2%-1.6pp | N/A | -100.0%-69.8pp | -22.9%+13.4pp | -50.6% | N/A | -30.1% | -36.3% |
| Return on Assets | -35.4%+7.3pp | N/A | -54.4%-29.5pp | -19.7%+7.5pp | -42.7%+15.6pp | N/A | -24.9%+315.3pp | -27.2%+268.3pp |
| Debt-to-Equity | 0.47+0.3x | 1.84+1.7x | 0.84+0.6x | 0.16-0.2x | 0.18 | 0.16 | 0.21 | 0.33 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Current Ratio, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Alzamend Neuro, Inc. ALZN | FY2026 | N/A | -$8.8M | N/A | $6.5M | — |
| Adial Pharmaceuticals, Inc ADIL | FY2025 | N/A | N/A | N/A | $9.7M | — |
| BRAINSTORM CELL THERAPUTC BCLI | FY2025 | N/A | N/A | N/A | $12.0M | — |
| TNF Pharmaceuticals, Inc. TNFA | FY2025 | N/A | -$11.6M | N/A | $9.6M | — |
| VYNE Therapeutics Inc. VYNE | FY2025 | $570K | -$26.5M | N/A | $19.1M | — |
| Impact BioMedical, Inc. IBO | FY2025 | $32K | -$11.8M | N/A | $34.0M | — |
Where Alzamend Neuro, Inc. Ranks
Frequently Asked Questions
Is Alzamend Neuro, Inc. profitable?
No, Alzamend Neuro, Inc. (ALZN) reported a net income of -$8.8M in fiscal year 2026.
What is Alzamend Neuro, Inc.'s EBITDA?
Alzamend Neuro, Inc. (ALZN) had EBITDA of -$8.7M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is Alzamend Neuro, Inc.'s return on equity (ROE)?
Alzamend Neuro, Inc. (ALZN) has a return on equity of -1196.4% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Alzamend Neuro, Inc.'s operating cash flow?
Alzamend Neuro, Inc. (ALZN) recorded an outflow of $8.1M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are Alzamend Neuro, Inc.'s total assets?
Alzamend Neuro, Inc. (ALZN) had $2.1M in total assets as of fiscal year 2026, including both current and long-term assets.
How much does Alzamend Neuro, Inc. spend on research and development?
Alzamend Neuro, Inc. (ALZN) invested $3.6M in research and development during fiscal year 2026.
What is Alzamend Neuro, Inc.'s debt-to-equity ratio?
Alzamend Neuro, Inc. (ALZN) had a debt-to-equity ratio of 1.84 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Alzamend Neuro, Inc.'s return on assets (ROA)?
Alzamend Neuro, Inc. (ALZN) had a return on assets of -421.9% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Alzamend Neuro, Inc.'s P/E ratio?
Alzamend Neuro, Inc. (ALZN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $6.5M as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Alzamend Neuro, Inc.'s price-to-sales ratio?
Alzamend Neuro, Inc. (ALZN) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $6.5M as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Alzamend Neuro, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, Alzamend Neuro, Inc. (ALZN) held $711K in cash, cash equivalents and investments, and reported an operating cash outflow of $8.1M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Alzamend Neuro, Inc.'s Piotroski F-Score?
Alzamend Neuro, Inc. (ALZN) has a Piotroski F-Score of 1 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Alzamend Neuro, Inc.'s earnings high quality?
Alzamend Neuro, Inc. (ALZN) reported a net loss of $8.8M while operations used $8.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Alzamend Neuro, Inc. cover its interest payments?
Alzamend Neuro, Inc. (ALZN) reported an operating loss of $8.8M against $7K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.